|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferon-α2b is FDA approved drug for the treatment of chronic HCV and HBV, melanoma, AIDS-related KS, carcinomas, hairy cell leukemia and chronic myelogenous leukemia.
|
31612813 |
2020 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The findings of this review include the following: The use of interferon-α2b will be restricted for patients with ulcerated primary melanoma in countries with no access to new drugs in adjuvant therapy.
|
31236710 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).
|
28135150 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, to determine if we could prevent the appearance of pCHSPCs in the PB, mice with humanized bone marrow-melanoma xenografts were administered Interferon α-2b, which is used clinically for treatment of melanoma.
|
23877751 |
2013 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferon-α2b (IFN-α2b) is used to treat melanoma but there is a need to improve its efficacy.
|
22306001 |
2012 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interferon (IFN)-β in preclinical studies, compared to IFN-α2, bound with higher affinity to its receptor, induced to higher levels of IFN-stimulated gene products, induced more apoptosis in melanoma cells, and had antitumor effects against melanoma.
|
21235385 |
2011 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis.
|
18281266 |
2008 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma.
|
18176117 |
2008 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Seventeen SN tested for loss of heterozygosity (LOH) at 9p and 10q regions, known to be frequently deleted in melanoma, showed LOH at the 9p loci D9S942 and IFNA.
|
17518771 |
2007 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
|
18332650 |
2007 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Temozolomide for the treatment of metastatic melanoma.
|
17576461 |
2007 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
|
17761969 |
2007 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
|
17709802 |
2007 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Malignant melanoma (MM) patients undergoing phase II-randomized chemoimmunotherapy trials were treated with DTIC, IFNalpha (Hoffmann-La Roche) (group A, n = 31), and with DTIC, IFNalpha and 13-cis-RA (Isotretinoin, Hoffmann-La Roche, Basel, Switzerland) (group B, n = 29).
|
17973783 |
2007 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study.
|
16939954 |
2006 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
|
17023156 |
2006 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Combined chemoimmunotherapy of metastatic melanoma: a single institution experience.
|
15917704 |
2005 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
|
16034308 |
2005 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.
|
16248763 |
2005 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
LOH was detected in 10 out of 27 informative naevi (37%) at D9S171 and in eight out of 19 (42%) at IFNA in the dissected naevus cell clusters, and in nine out of 27 (33%) at D9S171 and seven out of 19 (36%) at IFNA in the associated melanomas.
|
12690309 |
2003 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
|
12829675 |
2003 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
On the effect of biochemotherapy in metastatic malignant melanoma: an immunopathological evaluation.
|
12883367 |
2003 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study.
|
12393984 |
2002 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
|
12374674 |
2002 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha.
|
12439608 |
2002 |